Market closed
Cara Therapeutics/$CARA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cara Therapeutics
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Ticker
$CARA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
55
Website
CARA Metrics
BasicAdvanced
$19M
Market cap
-
P/E ratio
-$2.04
EPS
0.69
Beta
-
Dividend rate
Price and volume
Market cap
$19M
Beta
0.69
52-week high
$1.31
52-week low
$0.24
Average daily volume
527K
Financial strength
Current ratio
4.594
Quick ratio
4.204
Long term debt to equity
405.208
Total debt to equity
406.656
Interest coverage (TTM)
-23.35%
Management effectiveness
Return on assets (TTM)
-63.43%
Return on equity (TTM)
-184.32%
Valuation
Price to revenue (TTM)
1.71
Price to book
1.63
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-0.226
Growth
Revenue change (TTM)
-59.53%
Earnings per share change (TTM)
-1.67%
3-year revenue growth (CAGR)
-55.32%
3-year earnings per share growth (CAGR)
128.98%
What the Analysts think about CARA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cara Therapeutics stock.
CARA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CARA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cara Therapeutics stock?
Cara Therapeutics (CARA) has a market cap of $19M as of November 09, 2024.
What is the P/E ratio for Cara Therapeutics stock?
The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of November 09, 2024.
Does Cara Therapeutics stock pay dividends?
No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of November 09, 2024.
When is the next Cara Therapeutics dividend payment date?
Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cara Therapeutics?
Cara Therapeutics (CARA) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.